5398722025-10-012025-12-315398722025-04-012025-12-315398722025-10-012025-12-31in-capmkt:OtherExpenses1Member5398722025-10-012025-12-31in-capmkt:OtherExpenses2Member5398722025-10-012025-12-31in-capmkt:OtherExpenses3Member5398722025-10-012025-12-31in-capmkt:OtherExpenses4Member5398722025-10-012025-12-31in-capmkt:OtherExpenses5Member5398722025-10-012025-12-31in-capmkt:OtherExpenses6Member5398722025-10-012025-12-31in-capmkt:OtherExpenses7Member5398722025-10-012025-12-31in-capmkt:OtherExpenses8Member5398722025-10-012025-12-31in-capmkt:OtherExpenses9Member5398722025-10-012025-12-31in-capmkt:OtherExpenses10Member5398722025-04-012025-12-31in-capmkt:OtherExpenses1Member5398722025-04-012025-12-31in-capmkt:OtherExpenses2Member5398722025-04-012025-12-31in-capmkt:OtherExpenses3Member5398722025-04-012025-12-31in-capmkt:OtherExpenses4Member5398722025-04-012025-12-31in-capmkt:OtherExpenses5Member5398722025-04-012025-12-31in-capmkt:OtherExpenses6Member5398722025-04-012025-12-31in-capmkt:OtherExpenses7Member5398722025-04-012025-12-31in-capmkt:OtherExpenses8Member5398722025-04-012025-12-31in-capmkt:OtherExpenses9Member5398722025-04-012025-12-31in-capmkt:OtherExpenses10Member5398722025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15398722025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares539872BAJAJHCARENOTLISTEDINE411U01027BAJAJ HEALTHCARE LIMITEDMain BoardEquity2025-04-012026-03-312026-01-162026-01-12INRLakhsQuarterlyThird quarterSingle segmentPharmaceuticals2026-01-1616:15:002026-01-1617:00:00Not applicablefalsefalseDuring the quarter ended 31st December 2025, there was no default on Loans & Debt Securities.2025-10-012025-12-31UnauditedStandalone16122270001647100016286980006940900000112863000155866000588350007201100034258700014362520001924460000192446000031437000314370000161009000-5708000-1437000-42710000156738000187100015860900015791600055.15.01-0.14-0.144.964.870.00450.02430.04271. The above Financial Results of Bajaj Healthcare Limited (the 'Company') have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 16 January 2026. These results have been subjected to limited review by the Statutory auditors who have expressed an unmodified review conclusion. <BR> <BR> 2. The above un-audited financial results for the quarter and nine months ended 31 December 2025 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS),as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. <BR> <BR> 3. The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals. <BR> <BR> 4. In the year ended 31 March 2024, the Board of Directors had approved to sale disposal of undertaking unit(s) on going concern basis, situated at plot no. N92, L9.3 , T30, MIDC Tarapur, Taluka- Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D-2CH42 & D-2CH43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no.E-62 and E-63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal under Ind AS 105 ("Non-current Assets Held for Sale and Discontinued Operations"). The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Considering these assets are held for sale, the assets have been recorded at their fair value on the date these assets has been classified as held for sale. Out of these, one unit situated at plot no. N-92 was sold during the Quarter ended 31 March 2024. The total value of assets classified as held for sale represents lower of carrying value or fair value. <BR> <BR> The financial information from discontinued operations: <BR> Particulars Quarter Ended Nine Months Ended Year ended <BR> 31 Dec 2025 30 Sept 2025 31 Dec 2025 31 Dec 2025 31 Dec 2024 31 March 2025 <BR> (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) <BR> Total Income ( A ) (1.05) 0.05 65.40 1.10 95.88 58.07 <BR> Total Expenses ( B ) 56.03 179.05 183.13 282.61 408.96 459.18 <BR> Loss before Tax from Discontinued Operations ( C = A - B ) (57.08) (179.00) (117.73) (281.51) (313.08) (401.11) <BR> Tax Credit from Discontinued Operations ( D ) (14.37) (45.06) 206.71 (70.86) (11.27) (57.78) <BR> Loss after Tax from Discontinued Operations ( E = C - D ) (42.71) (133.94) (324.44) (210.65) (301.81) (343.33) <BR> <BR> <BR> 5. The Board of Directors of the Company in their meeting held on 10 July 2024 and the shareholders of the company in Extra-Ordinary General Meeting (“EGM”) held on 07 August 2024 through Video Conferencing (‘VC’) / Other Audio Visual Means (‘OAVM’) approved, the issue of 40,44,852 Equity Shares at Rs 338 per share (including premium at Rs. 333 per share) to Person(s) belonging to non-promoter category on preferential basis and the issue of convertible equity warrants 20,79,409 at Rs. 338 per warrant (including premium at Rs. 333 per share) to Person(s) belonging to promoter category as well as non-promoter category on preferential basis. The object of the issue is to repayment of term loan, investment in capital expenditure and general corporate purposes. The Company has also obtained the in-principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd. On 19 September 2024, post approval from Board, the Company has allotted 39,84,852 no. of equity shares and 20,79,409 convertible warrants and has also filed the relevant form with Registrar of Companies, Mumbai. The uncalled amount of share warrants as at 31 December 2025 is Rs. 5,271.30 lakhs and will be received within 18 months from the allotment date of 19 September 2024. <BR> <BR> 6. The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities. <BR> <BR> Particulars Rs. (in Lakhs) <BR> Repayment & prepayment of secured/unsecured loans from bank NBFC 15,000.00 <BR> General corporate purposes 225.90 <BR> Total 15,225.90 <BR> <BR> 7. In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) (“Genrx”), on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act, 1956. The acquisition was made for a total consideration of Rs. 1,085 lakhs. <BR> Subsequently, on 3 June 2025, the Company filed an application with the Hon’ble National Company Law Tribunal (‘NCLT’), Mumbai, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern, which is pending with NCLT as on 31 December 2025. Hence, Genrx has not been considered a subsidiary for consolidation purpose, pending requisite approvals from the NCLT, as control, defined under Ind AS 110 Consolidated Financial Statements is not established.2025-04-012025-12-31UnauditedStandalone45797390004177700046215160002140989000020785500046451500016667900019919700094496300041241980004973180000497318000090086000900860000407232000-28151000-7086000-2106500003861670005612000391779000157916000512.8912.68-0.67-0.6712.2212.010.00450.02270.0398Brokerage & Commission14909000Consumption of Stores Spares and Maintainence20343000Freight Forwarding & Transport45455000Legal & Professional Expenses21954000Miscellaneous Expenses12961000Power and Fuel83759000Processing & Labour Charges55664000Provision for Credit Loss10000000Travelling & Conveyence Expenses9696000Others67846000Brokerage & Commission35200000Consumption of Stores Spares and Maintainence144908000Freight Forwarding & Transport106126000Legal & Professional Expenses60917000Miscellaneous Expenses22683000Power and Fuel197088000Processing & Labour Charges143899000Provision for Credit Loss30000000Travelling & Conveyence Expenses26638000Others177504000Items that will not be reclassified to profit or loss25000002500000Items that will not be reclassified to profit or loss7500000750000062900018880000018710005612000